<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970955</url>
  </required_header>
  <id_info>
    <org_study_id>1633</org_study_id>
    <nct_id>NCT02970955</nct_id>
  </id_info>
  <brief_title>Prospecitve Observational Study on a Risk Adaptive Scheme for SBRT for Thoracic Nodes Metastases</brief_title>
  <official_title>Prospective Observational Study on a Risk Adaptive Scheme for Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable Thoracic Nodes Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oligometastatic patients with inoperable thoracic nodes metastases from any primary, except
      for hematologic malignancies, will undergo a risk adaptive scheme of stereotactic body
      radiation therapy (SBRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The observational study is designed to evaluate safety and efficacy of a risk adaptive scheme
      of stereotactic body radiation therapy (SRT) in oligometastatic patients with thoracic nodes
      metastases, medically inoperable, using VMAT RapidArc approach. The potential advantage of
      this technique is the ability to deliver a more selective irradiation to tumour's target
      while reducing doses to normal tissue, optimizing the therapeutic window.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Local control of disease</measure>
    <time_frame>7 years</time_frame>
    <description>Local control of the thoracic nodes stereotactic radiation therapy schedules for medically inoperable oligometastatic patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival for patients</measure>
    <time_frame>7 years</time_frame>
    <description>A measure of the activity of the SBRT treatment on the disease by statistical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival for patients</measure>
    <time_frame>7 years</time_frame>
    <description>Percentage of patients who are alive after a length of time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by EORTC QLQ C30 questionnaires</measure>
    <time_frame>7 years</time_frame>
    <description>At the end of the treatment and during the first follow-up appointment patients will complete the EORTC QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic and non-hematologic toxicities</measure>
    <time_frame>7 years</time_frame>
    <description>Hematologic and non-hematologic toxicities will be graded according to Common Terminology Criteria for Adverse Events version 4.0</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Thoracic Nodes Metastases</condition>
  <arm_group>
    <arm_group_label>Inoperable thoracic nodes metastases</arm_group_label>
    <description>Oligometastatic patients with inoperable thoracic nodes metastases from any primary</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inoperable thoracic nodes metastases</intervention_name>
    <description>The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues</description>
    <arm_group_label>Inoperable thoracic nodes metastases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with inoperable thoracic nodes metastases from any primary, except for hematologic
        malignancies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged &gt;18 years with ECOG 0-2

          -  Karnofsky index &gt; 70% (ECOG &gt;2)

          -  Any primary, except for hematologic malignancies

          -  DFI (Disease-free interval) from diagnosis &gt; 6 months

          -  Unresectable lesions or inoperable patients or patients who refused surgery

          -  Less than 3 metastatic thoracic nodes

          -  No extrathoracic disease or other metastatic sites stable or responding after
             chemotherapy, with less than 5 metastatic sites

          -  No life threatening conditions

          -  Chemotherapy completed at least 1 week before treatment

          -  Chemotherapy started at least 1 week after treatment allowed

          -  Systemic therapies other than chemotherapy allowed (i.e hormonal therapies and/or
             immunotherapy)

          -  Written informed consent

        Exclusion Criteria:

          -  Previous RT in the same region

          -  Pregnant women

          -  Patients with inability to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davide Franceschini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davide Franceschini, MD</last_name>
    <phone>+390282247428</phone>
    <email>davide.franceschini@cancercenter.humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Davide Franceschini</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Franceschini, MD</last_name>
      <phone>+390282247428</phone>
      <email>davide.franceschini@cancercenter.humanitas.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

